论文部分内容阅读
美国食品与药品管理局(FDA)与杨森制药宣布,Invokana(canagliflozin)已获准用于治疗成人2型糖尿病。Invokana是一类名为钠葡萄糖协同转运蛋白2抑制剂的新型药物中的一种。该药通过阻断肾脏葡萄糖重吸收、增加葡萄糖排泄而发挥降低血糖的作用,联合饮食与运动治疗,以改善、控制血糖。Invokana的安全性和有效性在临床试验中得到评估。结果显示,Invokana的耐受性良好。接受Invokana治疗的患者中,最常见的不良反应为生殖器霉菌(真
The U.S. Food and Drug Administration (FDA) and Janssen Pharmaceuticals announced that Invokana (canagliflozin) has been approved for the treatment of type 2 diabetes in adults. Invokana is a class of new drugs called sodium glucose co-transporter 2 inhibitors. The drug by blocking renal reabsorption of glucose, increase glucose excretion and play a role in lowering blood sugar, combined with diet and exercise therapy to improve and control blood sugar. The safety and efficacy of Invokana are evaluated in clinical trials. The results show that Invokana is well tolerated. Among the patients who received Invokana, the most common adverse reaction was genital mold